Alps Advisors Inc Belite Bio, Inc Transaction History
Alps Advisors Inc
- $14.5 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding BLTE
# of Institutions
12Shares Held
187KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY148KShares$6.88 Million0.09% of portfolio
-
State Street Corp Boston, MA15.7KShares$729,0140.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.31KShares$340,1070.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.7KShares$311,6840.0% of portfolio
-
Hrt Financial LP New York, NY5.41KShares$251,6260.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.16B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...